UBS AM
SGNT

UBS AM’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

UBS AM’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,600
Closed -$169K – 2696
2015
Q4 		$169K Buy
+10,600
New +$167K ﹤0.01% 2585
2015
Q3 		– Sell
-8,900
Closed -$216K – 2719
2015
Q2 		$216K Buy
+8,900
New +$213K ﹤0.01% 2553
2015
Q1 		– Sell
-8,100
Closed -$203K – 2655
2014
Q4 		$203K Buy
8,100
+1,100
+16% +$32.3K ﹤0.01% 2464
2014
Q3 		$218K Buy
+7,000
New +$190K ﹤0.01% 2323

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's SGNT Position: Q1 2016 in Review

UBS AM sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q1 2016, closing a stake of 10,600 shares — an estimated $169K sold.

UBS AM first reported a position in SGNT in Q3 2014 and held it in 4 quarters. The position peaked at $218K in Q3 2014. 136 funds tracked by Wall St. Rank hold SGNT as of Q1 2016.

  • UBS AM reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q1 2016 after selling out during the quarter.
  • UBS AM sold 10,600 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q1 2016, an estimated $169K.
  • UBS AM first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2014 and held it in 4 quarters.
  • UBS AM's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $218K in Q3 2014.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q1 2016.

Based on UBS AM's 13F filing for Q1 2016, filed 12 May 2016.